vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and FIRST MID BANCSHARES, INC. (FMBH). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $88.2M, roughly 1.9× FIRST MID BANCSHARES, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 3.4%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 5.0%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
First Mid Bancshares Inc. is a U.S.-headquartered regional financial services holding company. It provides full-range retail and commercial banking products, wealth management, insurance solutions, and agricultural financing, mainly serving individual consumers, small and medium-sized enterprises, and agricultural clients across multiple Midwestern states including Illinois, Missouri, and Indiana.
ESPR vs FMBH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $88.2M |
| Net Profit | — | $23.7M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 34.0% |
| Net Margin | — | 26.8% |
| Revenue YoY | 143.7% | 3.4% |
| Net Profit YoY | — | 23.5% |
| EPS (diluted) | $0.32 | $0.98 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $88.2M | ||
| Q3 25 | $87.3M | $89.3M | ||
| Q2 25 | $82.4M | $87.5M | ||
| Q1 25 | $65.0M | $84.3M | ||
| Q4 24 | $69.1M | $85.3M | ||
| Q3 24 | $51.6M | $80.6M | ||
| Q2 24 | $73.8M | $79.2M | ||
| Q1 24 | $137.7M | $79.9M |
| Q4 25 | — | $23.7M | ||
| Q3 25 | $-31.3M | $22.5M | ||
| Q2 25 | $-12.7M | $23.4M | ||
| Q1 25 | $-40.5M | $22.2M | ||
| Q4 24 | — | $19.2M | ||
| Q3 24 | $-29.5M | $19.5M | ||
| Q2 24 | $-61.9M | $19.7M | ||
| Q1 24 | $61.0M | $20.5M |
| Q4 25 | 50.6% | 34.0% | ||
| Q3 25 | -11.4% | 32.2% | ||
| Q2 25 | 8.6% | 34.4% | ||
| Q1 25 | -34.0% | 33.4% | ||
| Q4 24 | -6.4% | 29.7% | ||
| Q3 24 | -31.0% | 31.5% | ||
| Q2 24 | 3.5% | 33.7% | ||
| Q1 24 | 52.5% | 33.7% |
| Q4 25 | — | 26.8% | ||
| Q3 25 | -35.9% | 25.2% | ||
| Q2 25 | -15.4% | 26.8% | ||
| Q1 25 | -62.2% | 26.3% | ||
| Q4 24 | — | 22.5% | ||
| Q3 24 | -57.2% | 24.2% | ||
| Q2 24 | -83.9% | 24.9% | ||
| Q1 24 | 44.3% | 25.6% |
| Q4 25 | $0.32 | $0.98 | ||
| Q3 25 | $-0.16 | $0.94 | ||
| Q2 25 | $-0.06 | $0.98 | ||
| Q1 25 | $-0.21 | $0.93 | ||
| Q4 24 | $-0.14 | $0.81 | ||
| Q3 24 | $-0.15 | $0.81 | ||
| Q2 24 | $-0.33 | $0.82 | ||
| Q1 24 | $0.34 | $0.86 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | $354.5M |
| Stockholders' EquityBook value | $-302.0M | $958.7M |
| Total Assets | $465.9M | $8.0B |
| Debt / EquityLower = less leverage | — | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
| Q4 25 | — | $354.5M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-302.0M | $958.7M | ||
| Q3 25 | $-451.4M | $932.2M | ||
| Q2 25 | $-433.5M | $894.1M | ||
| Q1 25 | $-426.2M | $870.9M | ||
| Q4 24 | $-388.7M | $846.4M | ||
| Q3 24 | $-370.2M | $858.5M | ||
| Q2 24 | $-344.2M | $813.6M | ||
| Q1 24 | $-294.3M | $798.0M |
| Q4 25 | $465.9M | $8.0B | ||
| Q3 25 | $364.0M | $7.8B | ||
| Q2 25 | $347.1M | $7.7B | ||
| Q1 25 | $324.0M | $7.6B | ||
| Q4 24 | $343.8M | $7.5B | ||
| Q3 24 | $314.1M | $7.6B | ||
| Q2 24 | $352.3M | $7.6B | ||
| Q1 24 | $373.1M | $7.7B |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $130.9M |
| Free Cash FlowOCF − Capex | — | $124.0M |
| FCF MarginFCF / Revenue | — | 140.6% |
| Capex IntensityCapex / Revenue | 0.0% | 7.8% |
| Cash ConversionOCF / Net Profit | — | 5.53× |
| TTM Free Cash FlowTrailing 4 quarters | — | $207.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $130.9M | ||
| Q3 25 | $-4.3M | $33.0M | ||
| Q2 25 | $-31.4M | $7.7M | ||
| Q1 25 | $-22.6M | $47.9M | ||
| Q4 24 | $-35.0M | $124.4M | ||
| Q3 24 | $-35.3M | $33.1M | ||
| Q2 24 | $-7.2M | $24.0M | ||
| Q1 24 | $53.8M | $29.0M |
| Q4 25 | — | $124.0M | ||
| Q3 25 | — | $31.9M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | — | $46.0M | ||
| Q4 24 | — | $119.5M | ||
| Q3 24 | $-35.5M | $32.0M | ||
| Q2 24 | $-7.3M | $22.9M | ||
| Q1 24 | $53.8M | $27.6M |
| Q4 25 | — | 140.6% | ||
| Q3 25 | — | 35.8% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | 54.5% | ||
| Q4 24 | — | 140.0% | ||
| Q3 24 | -68.7% | 39.7% | ||
| Q2 24 | -9.9% | 28.9% | ||
| Q1 24 | 39.0% | 34.5% |
| Q4 25 | 0.0% | 7.8% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 2.0% | ||
| Q1 25 | 0.0% | 2.3% | ||
| Q4 24 | 0.0% | 5.8% | ||
| Q3 24 | 0.3% | 1.4% | ||
| Q2 24 | 0.1% | 1.4% | ||
| Q1 24 | 0.1% | 1.9% |
| Q4 25 | — | 5.53× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 0.33× | ||
| Q1 25 | — | 2.16× | ||
| Q4 24 | — | 6.49× | ||
| Q3 24 | — | 1.70× | ||
| Q2 24 | — | 1.21× | ||
| Q1 24 | 0.88× | 1.42× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FMBH
Segment breakdown not available.
